Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Bao Pharmaceuticals CoHKSE:02659 +0.25%9 Gross Margin % is 28.27% as of Dec. 2025, which is 68% below its 10-year median of 89.00. GuruFocus rates HKSE:02659 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 735 Biotechnology companies, Shanghai Bao Pharmaceuticals Co ranks better than 82.86% on this metric.
Shanghai Bao Pharmaceuticals Co (HKSE:02659) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Shanghai Bao Pharmaceuticals Co had a gross margin of 28.27% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Shanghai Bao Pharmaceuticals Co Gross Margin % Related Terms
Shanghai Bao Pharmaceuticals Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Bao Pharmaceuticals Co Gross Margin % Chart
Shanghai Bao Pharmaceuticals Co Annual Data
Trend
Dec23
Dec24
Dec25
Gross Margin %
97.85
81.50
89.00
Shanghai Bao Pharmaceuticals Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Gross Margin %
0.00
69.78
85.24
99.37
28.27
HKSE:02659 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Shanghai Bao Pharmaceuticals Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Bao Pharmaceuticals Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Bao Pharmaceuticals Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Bao Pharmaceuticals Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a Gross Margin % of 28.27% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors. This is 68% below median its historical median of 89.00. Over the past decade, Shanghai Bao Pharmaceuticals Co's Gross Margin % has ranged from 81.50 to 97.85. According to the industry distribution chart, Shanghai Bao Pharmaceuticals Co ranks #126 out of 735 companies in the Biotechnology industry, placing it in the top 17.1%.
Is Shanghai Bao Pharmaceuticals Co's Gross Margin % too high?
Shanghai Bao Pharmaceuticals Co's current Gross Margin % of 28.27% is 68% below median its 10-year median of 89.00. Over the past 10 years, this metric has ranged from a low of 81.50 to a high of 97.85. The Biotechnology industry median Gross Margin % is 60.91. Shanghai Bao Pharmaceuticals Co's value of 28.27% is 53.6% below this industry median. Based on the distribution chart, Shanghai Bao Pharmaceuticals Co ranks #126 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Bao Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Bao Pharmaceuticals Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Bao Pharmaceuticals Co ranks #126 out of 735 companies for Gross Margin %. This places Shanghai Bao Pharmaceuticals Co in the top 17% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Shanghai Bao Pharmaceuticals Co's value of 28.27% is 53.6% below this benchmark. Historically, Shanghai Bao Pharmaceuticals Co's own Gross Margin % has ranged from 81.50 to 97.85 over the past decade. While the company's 10-year median is 89.00 vs. the industry median of 60.91, Shanghai Bao Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Bao Pharmaceuticals Co's current Gross Margin % of 28.27% is 53.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Bao Pharmaceuticals Co's current Gross Margin % is 28.27%, which is 68% below median its own 10-year median of 89.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Bao Pharmaceuticals Co stock overvalued right now?
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a current Gross Margin % of 28.27%. The current Gross Margin % is 28.27%, which is 68% below median its 10-year median of 89.00 and 53.6% below the Biotechnology industry median of 60.91. Shanghai Bao Pharmaceuticals Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Shanghai Bao Pharmaceuticals Co (HKSE:02659), the current Gross Margin % is 28.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai Bao Pharmaceuticals Co Ltd is a biotechnology company with an approved product and a diverse clinical pipeline, leveraging synthetic biology technology to develop and deliver recombinant biologic drugs in China, targeting conditions with limited treatment options and complex manufacturing challenges. The company has proprietary technology platforms, supported by its chassis cell engineering technology, that combine drug design and bioprocessing capabilities. It has production lines for finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes. The group has only one reportable operating segment, which is the research, development, and commercialisation of pharmaceutical products.
9GF Score
Get the complete analysis for HKSE:02659
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02659 has been successfully added to your 
